Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off
source: pixabay.com

Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off

According to a story from biopharmadive.com, the race to a hemophilia A gene therapy continues to tighten following a recent release of early data from Sangamo Therapeutics and Pfizer. The…

Continue Reading Latest Data Release From Clinical Trial Suggests That Hemophilia A Gene Therapy Isn’t Far Off

Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year

According to a publication from Reuters, based on early clinical data, American biotechnology company BioMarin Pharmaceuticals believes that a single injection of its experimental hemophilia A drug could relieve symptoms…

Continue Reading Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year
Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients
source: pixabay.com

Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients

According to a story from BioSpace, a recent study revealed that hemophilia A patients were less likely to experience bleeds when they used new, extended half-life therapies on a preventive…

Continue Reading Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients
Patient Deaths While Taking Hemlibra Have Been Linked to Other Causes, Investigators Say
source: pixabay.com

Patient Deaths While Taking Hemlibra Have Been Linked to Other Causes, Investigators Say

According to a story from biopharmadive.com, the pharmaceutical company Roche is reporting a total of five deaths of patients with hemophilia A that have taken the company's product Hemlibra. While…

Continue Reading Patient Deaths While Taking Hemlibra Have Been Linked to Other Causes, Investigators Say